{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:38:27Z","timestamp":1794008307096,"version":"4.8.0"},"reference-count":94,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2024,1,31]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Age-related macular degeneration is a major cause of blindness, and the development of anti-vascular endothelial growth factor (VEGF) intravitreal treatments has revolutionised the management of the disease. At the same time, new challenges and unmet needs arose due to the limitations of the current therapeutic options. Neovascularisation development during the course of the disease has a complex pathogenetic mechanism, and several biomarkers and their association with treatment outcomes have been investigated. We reviewed the relevant literature about neovascularisation development and biomarkers related to response to treatment. Improving our knowledge on the field can improve patient outcomes and offer personalised care.<\/jats:p>","DOI":"10.1136\/bmjophth-2023-001516","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T04:30:25Z","timestamp":1707539425000},"page":"e001516","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response\u2014a scoping review"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7269-2785","authenticated-orcid":false,"given":"Nikolaos","family":"Dervenis","sequence":"first","affiliation":[{"name":"Aristotle University of Thessaloniki, Thessaloniki, Greece"},{"name":"Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Dervenis","sequence":"additional","affiliation":[{"name":"Colchester Hospital University NHS Foundation Trust, Colchester, Essex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-9379","authenticated-orcid":false,"given":"Eleftherios","family":"Agorogiannis","sequence":"additional","affiliation":[{"name":"Uveitis and Medical Retina, Manchester Royal Eye Hospital, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"2025090109232997000_9.1.e001516.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.7.716"},{"key":"2025090109232997000_9.1.e001516.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314422"},{"key":"2025090109232997000_9.1.e001516.3","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-008-9327-4"},{"key":"2025090109232997000_9.1.e001516.4","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl238"},{"key":"2025090109232997000_9.1.e001516.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2008.05.001"},{"key":"2025090109232997000_9.1.e001516.6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/11206721211001716","article-title":"Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: Results of the AMD-MANAGE study","volume":"32","author":"Pina Mar\u00edn","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.7","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.2147\/OPTH.S275977","article-title":"Trends in real-world neovascular AMD treatment outcomes in the UK","volume":"14","author":"Mehta","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular Age-Related Macular Degeneration (nAMD): a review of emerging treatment options","volume":"16","author":"Tan","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.04.003"},{"key":"2025090109232997000_9.1.e001516.10","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113989"},{"key":"2025090109232997000_9.1.e001516.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.06.045"},{"key":"2025090109232997000_9.1.e001516.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2013.07.003"},{"key":"2025090109232997000_9.1.e001516.13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01399","article-title":"Contribution of angiogenesis to inflammation and cancer","volume":"9","author":"Aguilar-Cazares","year":"2019","journal-title":"Front Oncol"},{"key":"2025090109232997000_9.1.e001516.14","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.2006.2.3.213"},{"key":"2025090109232997000_9.1.e001516.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(02)00635-8"},{"key":"2025090109232997000_9.1.e001516.16","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1996.0098"},{"key":"2025090109232997000_9.1.e001516.17","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911423031"},{"key":"2025090109232997000_9.1.e001516.18","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ . Optical coherence tomography and the development of antiangiogenic therapies in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2016;57. doi:10.1167\/iovs.16-19969","DOI":"10.1167\/iovs.16-19969"},{"key":"2025090109232997000_9.1.e001516.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.11.004"},{"key":"2025090109232997000_9.1.e001516.20","doi-asserted-by":"publisher","DOI":"10.1159\/000517520"},{"key":"2025090109232997000_9.1.e001516.21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2021.08.006","article-title":"Multimodal imaging comparison of polypoidal choroidal vasculopathy between asian and caucasian populations","volume":"234","author":"Corvi","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.22","doi-asserted-by":"publisher","DOI":"10.2174\/157339911797415620"},{"key":"2025090109232997000_9.1.e001516.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2147-8"},{"key":"2025090109232997000_9.1.e001516.24","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4968"},{"key":"2025090109232997000_9.1.e001516.25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2017.05.021","article-title":"Choroidal changes associated with subretinal drusenoid deposits in age-related macular degeneration using swept-source optical coherence tomography","volume":"180","author":"La\u00edns","year":"2017","journal-title":"American Journal of Ophthalmology"},{"key":"2025090109232997000_9.1.e001516.26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00109-013-1050-0","article-title":"An eye on the future of inflammasomes and drug development in AMD","volume":"91","author":"Campbell","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"2025090109232997000_9.1.e001516.27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2717"},{"key":"2025090109232997000_9.1.e001516.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408835103"},{"key":"2025090109232997000_9.1.e001516.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72066-5"},{"key":"2025090109232997000_9.1.e001516.30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.omtn.2019.07.018","article-title":"Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease","volume":"17","author":"Matsuda","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025090109232997000_9.1.e001516.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01624-0"},{"key":"2025090109232997000_9.1.e001516.32","doi-asserted-by":"publisher","DOI":"10.1080\/09273940590909185"},{"key":"2025090109232997000_9.1.e001516.33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.491"},{"key":"2025090109232997000_9.1.e001516.34","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6002"},{"key":"2025090109232997000_9.1.e001516.35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4103\/jovr.jovr_67_18","article-title":"Negative regulators of angiogenesis, ocular vascular homeostasis, and pathogenesis and treatment of exudative AMD","volume":"13","author":"Farnoodian","year":"2018","journal-title":"J Ophthalmic Vis Res"},{"key":"2025090109232997000_9.1.e001516.36","first-page":"353","article-title":"Age-related macular degeneration (AMD): pathogenesis and therapy","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol Rep"},{"key":"2025090109232997000_9.1.e001516.37","first-page":"2428","article-title":"Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor","volume":"43","author":"Mori","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109232997000_9.1.e001516.38","first-page":"1994","article-title":"AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization","volume":"43","author":"Mori","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109232997000_9.1.e001516.39","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10026"},{"key":"2025090109232997000_9.1.e001516.40","doi-asserted-by":"publisher","DOI":"10.1001\/archopthalmol.2011.1892"},{"key":"2025090109232997000_9.1.e001516.41","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.598"},{"key":"2025090109232997000_9.1.e001516.42","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5322.48"},{"key":"2025090109232997000_9.1.e001516.43","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5322.55"},{"key":"2025090109232997000_9.1.e001516.44","first-page":"1617","article-title":"Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells","volume":"42","author":"Hangai","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109232997000_9.1.e001516.45","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2025090109232997000_9.1.e001516.46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165934","article-title":"Matrix metalloproteinases in age-related macular degeneration (AMD)","volume":"21","author":"Garc\u00eda-Onrubia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025090109232997000_9.1.e001516.47","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.889887"},{"issue":"Pt 4","key":"2025090109232997000_9.1.e001516.48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/eye.1997.137","article-title":"Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity","volume":"11 (Pt 4)","author":"Sarks","year":"1997","journal-title":"Eye (Lond)"},{"key":"2025090109232997000_9.1.e001516.49","doi-asserted-by":"publisher","DOI":"10.1076\/0271-3683(200009)21:3;1-R;FT684"},{"key":"2025090109232997000_9.1.e001516.50","first-page":"2194","article-title":"Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes","volume":"39","author":"Steen","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109232997000_9.1.e001516.51","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.83.3.233"},{"key":"2025090109232997000_9.1.e001516.52","article-title":"The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration","volume":"5","author":"Campochiaro","year":"1999","journal-title":"Mol Vis"},{"key":"2025090109232997000_9.1.e001516.53","first-page":"2309","article-title":"Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization","volume":"41","author":"Murata","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109232997000_9.1.e001516.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65430-2"},{"key":"2025090109232997000_9.1.e001516.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"2025090109232997000_9.1.e001516.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2025090109232997000_9.1.e001516.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.006"},{"key":"2025090109232997000_9.1.e001516.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2014.11.002"},{"key":"2025090109232997000_9.1.e001516.59","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.77"},{"key":"2025090109232997000_9.1.e001516.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.01.030"},{"key":"2025090109232997000_9.1.e001516.61","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2147\/OPTH.S11627","article-title":"Update on the role of genetics in the onset of age-related macular degeneration","volume":"5","author":"Francis","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.056"},{"key":"2025090109232997000_9.1.e001516.63","first-page":"1680","article-title":"Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients","volume":"20","author":"Park","year":"2014","journal-title":"Mol Vis"},{"key":"2025090109232997000_9.1.e001516.64","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.43"},{"key":"2025090109232997000_9.1.e001516.65","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ophtha.2013.10.047","article-title":"Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration","volume":"121","author":"Hermann","year":"2014","journal-title":"Ophthalmology"},{"key":"2025090109232997000_9.1.e001516.66","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.ophtha.2015.04.024","article-title":"VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy in age-related macular degeneration","volume":"122","author":"Hagstrom","year":"2015","journal-title":"Ophthalmology"},{"key":"2025090109232997000_9.1.e001516.67","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1111\/aos.13519","article-title":"Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration","volume":"96","author":"Cobos","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.68","first-page":"1987","article-title":"A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration","volume":"7","author":"Kitchens","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.69","first-page":"702","article-title":"Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population","volume":"19","author":"Chang","year":"2013","journal-title":"Mol Vis"},{"key":"2025090109232997000_9.1.e001516.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.05.018"},{"key":"2025090109232997000_9.1.e001516.71","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1111\/aos.12587","article-title":"Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration","volume":"93","author":"Piermarocchi","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.72","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000446819","article-title":"Genetic risk evaluation in wet age-related macular degeneration treatment response","volume":"236","author":"Chaudhary","year":"2016","journal-title":"Ophthalmologica"},{"key":"2025090109232997000_9.1.e001516.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.05.025"},{"key":"2025090109232997000_9.1.e001516.74","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.150995"},{"key":"2025090109232997000_9.1.e001516.75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042464","article-title":"Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS ONE"},{"key":"2025090109232997000_9.1.e001516.76","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/13816810.2014.955585","article-title":"Investigating the CFH gene polymorphisms as a risk factor for age-related macular degeneration in an Iranian population","volume":"37","author":"Babanejad","year":"2016","journal-title":"Ophthalmic Genet"},{"key":"2025090109232997000_9.1.e001516.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.11.037"},{"key":"2025090109232997000_9.1.e001516.78","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109557"},{"key":"2025090109232997000_9.1.e001516.79","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1111\/aos.14970","article-title":"Genetic associations of anti-vascular endothelial growth factor therapy response in age-related macular degeneration: a systematic review and meta-analysis","volume":"100","author":"Wang","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.80","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/IAE.0000000000002454","article-title":"Genetics of large pigment epithelial detachments in neovascular age-related macular degeneration","volume":"40","author":"Mouallem-Beziere","year":"2020","journal-title":"Retina"},{"key":"2025090109232997000_9.1.e001516.81","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/eye.2008.28","article-title":"Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy","volume":"23","author":"Brantley","year":"2009","journal-title":"Eye (Lond)"},{"key":"2025090109232997000_9.1.e001516.82","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31822a2c7c"},{"key":"2025090109232997000_9.1.e001516.83","first-page":"2598","article-title":"Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration","volume":"16","author":"Teper","year":"2010","journal-title":"Mol Vis"},{"key":"2025090109232997000_9.1.e001516.84","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2012.26.6.414"},{"key":"2025090109232997000_9.1.e001516.85","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.612812","article-title":"Age-related macular degeneration revisited: from pathology and cellular stress to potential therapies","volume":"8","author":"Hadziahmetovic","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025090109232997000_9.1.e001516.86","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-019-0197-3","article-title":"Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects","volume":"13","author":"Mohamad","year":"2019","journal-title":"Hum Genomics"},{"key":"2025090109232997000_9.1.e001516.87","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4103\/tjo.tjo_72_19","article-title":"Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in hispanic population","volume":"9","author":"Rodr\u00edguez","year":"2019","journal-title":"Taiwan J Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.88","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1097\/IAE.0000000000000258","article-title":"Polymorphisms in the APOE gene and the location of retinal fluid in eyes with neovascular age-related macular degeneration","volume":"34","author":"Wickremasinghe","year":"2014","journal-title":"Retina"},{"key":"2025090109232997000_9.1.e001516.89","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09632-0","article-title":"A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration","volume":"7","author":"Yamashiro","year":"2017","journal-title":"Sci Rep"},{"key":"2025090109232997000_9.1.e001516.90","first-page":"2578","article-title":"Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration","volume":"18","author":"Wang","year":"2012","journal-title":"Mol Vis"},{"key":"2025090109232997000_9.1.e001516.91","doi-asserted-by":"crossref","first-page":"37924","DOI":"10.1038\/srep37924","article-title":"GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration","volume":"6","author":"Riaz","year":"2016","journal-title":"Sci Rep"},{"key":"2025090109232997000_9.1.e001516.92","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamaophthalmol.2015.0369","article-title":"Genetic testing for age-related macular degeneration","volume":"133","author":"Stone","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2025090109232997000_9.1.e001516.93","doi-asserted-by":"publisher","DOI":"10.1586\/17469899.2.3.443"},{"key":"2025090109232997000_9.1.e001516.94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/aos.15232","article-title":"Common and rare genetic risk variants in age-related macular degeneration and genetic risk score in the Coimbra eye study","volume":"101","author":"Farinha","year":"2023","journal-title":"Acta Ophthalmol"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2023-001516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:23:44Z","timestamp":1756743824000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2023-001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,10]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bmjophth-2023-001516"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2023-001516","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}